1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Skin cancer

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma

Technology appraisal guidance [TA766] Published: 02 February 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 144 KB 02 February 2022  
  • Register of interests PDF 122 KB 02 February 2022  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 217 KB 17 December 2021  
  • Committee papers PDF 5.97 MB 17 December 2021  
  • Public committee slides PDF 1.51 MB 17 December 2021  

Invitation to participate

  • Final scope PDF 174 KB 07 July 2021  
  • Final stakeholder list PDF 187 KB 07 July 2021  

Final draft guidance: TA553

  • Final draft guidance: TA553  
  • Final appraisal document - TA553 PDF 290 KB 20 November 2018  
  • Committee papers - TA553 PDF 15.28 MB 19 November 2018  
  • Public committee slides - TA553 PDF 1.13 MB 19 November 2018  
  • Final appraisal document - managed access agreement - TA553 PDF 547 KB 26 November 2018  
  • Final appraisal document - equality impact assessment - TA553 PDF 222 KB 19 December 2018  
  • Committee papers - register of interests - TA553 PDF 125 KB 03 April 2019  

Invitation to participate

  • Final scope - TA553 PDF 224 KB 16 April 2018  
  • Final stakeholder list - TA553 PDF 260 KB 16 April 2018  
  • NICE's response to comments on the draft scope and provisional stakeholder list - TA553 PDF 206 KB 16 April 2018  
  • Equality impact assessment (Scoping) - TA553 PDF 173 KB 16 April 2018